Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Condition:   Solid Tumors
Interventions:   Drug: LHC165;   Biological: PDR001
Sponsor:   Novartis Pharmaceuticals
Not yet recruiting

http://ift.tt/2xVE7bJ